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doi:10.1016/j.ejvs.2011.11.007Letter to Editor Re “Differential Protein Expression in Serum of
Abdominal Aortic Aneurysm Patients – A Proteomic Approach”Dear Editor,
In their paper “Differential expression in serum of abdominal
aortic aneurysm patients – A proteomic approach”, Pulinx et al.1
mined the proteome of patients with AAAs in search of novel
biomarkers. They report elevated factor XII and a-1 antitrypsin
levels in the serum of patients with progressive aneurysms, but
found these proteins to have little ability to predict aneurysm
progression above the established marker, AAA diameter.
I propose that the authors were never likely to discover a puta-
tive biomarker using this technique. DIGE has been utilised by
scientists across medicine and vascular surgery [including our
group] for many years, and although it has provided insight into
disease pathogenesis, it has failed to discover a biomarker translat-
able to clinical practice.2
Serum is an unstable sensitive protein preparation, which can
modify depending on harvest factors including time-of-day,
ambient temperature, current health, sex, and age, all factors which
have not been controlled for in this study.3 Given this principle ﬂaw,
and the most signiﬁcant ﬁnding being increased expression of
ubiquitous Albumin in patients with large AAAs [P ¼ 0.007], the
results must be interpreted with caution.
I do acknowledge the authors correct closing comments that
“further research, with larger sample sizes” are appropriate. It
should be emphasised that this should be in the form of a multi-
centre, prospective, protocol driven study using blood plasma
[a more stable protein suspension]. The analysis should utilise
high-throughput proteomic techniques obviating the potential
confounders caused by protein fractionation and enrichment that
limit DIGE.DOI of original article: 10.1016/j.ejvs.2011.11.024.References
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doi:10.1016/j.ejvs.2011.11.021Response to Letter to Editor re “Differential Protein Expression
in Serum of Abdominal Aortic Aneurysm Patients – A
Proteomic Approach”Dear Editor,
We would like to thank Dr. Nordon for his interest in
and remarks on our manuscript. We fully agree that the transla-
tion of proteomics-discovered biomarkers into clinically mean-
ingful assays is difﬁcult. However, our aim was to ﬁnd
differential protein expression related to aneurysm size and
progression. These differentially expressed proteins could
help to elucidate the mechanisms behind abdominal aortic
aneurysm.
Furthermore, standardization of sample collection and process-
ing procedures is crucial, since they can have a dramatic effect on
quality and reproducibility of the obtained results. To obtain
comparable and reproducible results, we collected, processed and
stored all our samples in a highly standardized way. Indeed, it is
known that age, sex and several other factors can inﬂuence the
protein expression pattern in serum. Therefore, we used linear
regression to control for possible bias due to age, sex and peripheral
arterial disease (PAD) and our found associations remained
signiﬁcant.
As Dr. Nordon correctly emphasizes, further research with larger
sample sizes is necessary. Therefore, we are still including AAA
patients in a standardized follow-up regime. We are planning to
analyze the protein expression patterns in serum, EDTA plasma as
well as citrate plasma.B. Pulinx
Department of Clinical Chemistry, Maastricht University
Medical Center, The NetherlandsDOI of original article: 10.1016/j.ejvs.2011.11.021.
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doi:10.1016/j.ejvs.2011.11.024Re: Single-centre Prospective Comparison between Contrast-
enhanced Ultrasound and Computed Tomography Angiography
after EVARDifﬁculties of Using Contrast Enhanced Ultrasound for EVAR
Surveillance
We would like to commend you for your work and we were
delighted to read your ﬁve-year comparison of CEUS and CTA for
EVAR surveillance.1 This is to our knowledge the largest series to
compare these two modalities and we are keen advocates of
CEUS for EVAR surveillance also having achieved similar results
to you in our department. Currently we are using three techniques
for our surveillance, we are comparing CTAwith duplex ultrasound
and also CEUS for selective cases.
We have a few questions regarding your work. Firstly your
methods section states that three angiologists, who were experi-
enced in vascular ultrasonography performed all the scans. Did
they all perform equal amounts of scans and also was their prior
experience of using microbubble contrast the same? In our practice
we found the most experienced ultrasonographers have better
results and pick up rates that are more comparable to CT scanning
than those who are novices of the technique.
We felt that your CTA scans performed included extremely high
radiation doses, they are triple phase studies and also include the
thoracic aorta. As a routinet we normally start from the lower
cuts of the thorax and just cover the abdominal aorta and femoral
arteries. Our practise for thoracoabdominal aneurysms however is
obviously different to this but for the standard infrarenal EVAR weDOI of original article: 10.1016/j.ejvs.2011.11.011.do not include thoracic cuts. Have you calculated the radiation
exposure to your patients from CTA surveillance? We were also
wondering if during your CTA surveillance programme, that you
measured periodic renal functions and noted any changes with
the use of iodinated contrast? Did the implementation of pre-
scanning intravenous hydration make any difference to renal func-
tion in your high-risk renotoxic patient cohort?
We were also interested to note the amount of contrast used for
your studies, clinically we use a smaller dose of approximately 1 ml
of SonoVue for each of our scans and repeat with a further 1 ml if
required. Were any microbubble costings recorded? We were
wondering how much more it costs to perform CEUS compared
with unenhanced duplex scans. In our centre, we have had to
have a Physician present to provide vascular access and to manage
potential adverse side effects, when using CEUS, which obviously
increases the cost dramatically. We were also wondering what
the corresponding CTA costs were?
Lastly, we would like to ask if the use of abdominal radiography
in conjunction with CEUS was implemented during this study and
did it affect the increased detection of migration or stent fractures.
There is no mention in your paper of these ﬁndings.
Overall, we found your study extremely helpful and would no
doubt help us in our pursuit to implement contrast-enhanced ultra-
sound scanning to our practice and also practice of others in the UK.Reference
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doi:10.1016/j.ejvs.2011.11.012Response to Letter to the Editor “Re: Single Centre Prospective
Comparison between Contrast Enhanced UltraSound and
Computed Tomography Angiography after EVAR”Dear Editor,
We are grateful for the comments of Drs. S. Dindyal and C. Kyr-
iakides. They raise several important issues:DOI of original article: 10.1016/j.ejvs.2011.11.012.
